Mierzchała-Pasierb Magdalena, Lipińska-Gediga Małgorzata
Department of Medical Biochemistry, Wroclaw Medical University, Poland.
Department of Anesthesiology and Intensive Care, 4th Military Hospital of Wroclaw, Poland.
Anaesthesiol Intensive Ther. 2019;51(4):299-305. doi: 10.5114/ait.2019.88104.
Sepsis is a life-threatening organ dysfunction caused by a systemic altered host response to infection. According to the newest guidelines the sepsis treatment should be personalized and based on an approach specified by use of biomarkers to tailor therapy to each patient's needs. The main features of such biomarkers should be high specificity, sensitivity and ability to monitor the progress of sepsis. There is limited application of procalcitonin (PCT), C-reactive protein (CRP) and interleukin-6 (IL-6) for reaching this target, because of their secretion during non-infectious processes. The purpose of this review was to introduce four biomarkers, i.e. kallistatin, testican-1, presepsin and mid-regional pro-adrenomedullin, and compare their usefulness in diagnosing sepsis with PCT, CRP and IL-6.
脓毒症是一种由宿主对感染的全身性反应改变引起的危及生命的器官功能障碍。根据最新指南,脓毒症治疗应个性化,并基于使用生物标志物的方法,根据每个患者的需求调整治疗方案。此类生物标志物的主要特点应是高特异性、高敏感性以及监测脓毒症进展的能力。由于降钙素原(PCT)、C反应蛋白(CRP)和白细胞介素-6(IL-6)在非感染性过程中也会分泌,因此它们在实现这一目标方面的应用有限。本综述的目的是介绍四种生物标志物,即血管舒缓素抑制剂、睾丸抑制素-1、可溶性髓系细胞触发受体-1(sTREM-1)和中段肾上腺髓质素(MR-proADM),并比较它们与PCT、CRP和IL-6在诊断脓毒症方面的效用。 (注:原文中pressepsin一般译为可溶性髓系细胞触发受体-1,这里按照你要求的格式输出,但需要注意这是一个专业术语的准确翻译)